We performed a meta-analysis of fatigue associated with the use of everolimus, temsirolimus or ridaforolimus in patients with solid tumors. Eligible studies included randomized trials of patients with solid tumors on everolimus, temsirolimus or ridaforolimus describing events of fatigue. A total of 18 clinical trials including 8143 patients were considered eligible for the meta-analysis. On the basis of random-effects model, we found that the relative risk of all-grade and high-grade fatigue were 1.26 [95% CI: 1.09-1.46; p < 0.0001], 1.49 [95% CI: 0.99, 2.24; p = 0.05], respectively. On subgroup analysis, we cannot identify any difference between everolimus and temsirolimus in the risk of fatigue. Thus, our meta-analysis has demonstrated that regimens containing everolimus, temsirolimus or ridaforolimus for the treatment of solid tumors are associated with an increased risk of all-grade fatigue, whereas the risk of high-grade fatigue did not reach the threshold of statistical significance. Close clinical monitoring and pre-emptive treatment for fatigue are recommended.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14737140.2015.1014342 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials.
Pharmacol Res
January 2025
Department of Systems Medicine, University of Rome Tor Vergata, Rome 00133, Italy.
Glioblastoma (GBM) is the most common and lethal primary brain tumor. The standard treatment for newly diagnosed GBM includes surgical resection, when feasible, followed by radiotherapy and temozolomide-based chemotherapy. Upon disease progression, the anti-vascular endothelial growth factor-A (VEGF-A) monoclonal antibody bevacizumab, can be considered.
View Article and Find Full Text PDFBioinformatics analysis of the mechanisms of traumatic brain injury-associated dementia based on the competing endogenous RNA.
Psychopharmacology (Berl)
December 2024
Translational Pharmaceutical Laboratory, Jining First People's Hospital, Jining, Shandong, 272000, China.
Rationale: Traumatic brain injury (TBI) is a critical condition associated with cognitive impairments, including dementia. This study is aimed to construct a long noncoding RNA (lncRNA)-microRNA (miRNA)-messenger RNA (mRNA) network based on bioinformatics analysis and explore molecular mechanisms underlying post-TBI dementia.
Methods: GSE104687 and GSE205661 datasets were downloaded from Gene Expression Omnibus database.
mTOR Dysregulation, Insulin Resistance, and Hypertension.
Biomedicines
August 2024
Emergency Discipline, University Hospital of Bucharest, 050098 Bucharest, Romania.
Worldwide, diabetes mellitus (DM) and cardiovascular diseases (CVDs) represent serious health problems associated with unhealthy diet and sedentarism. Metabolic syndrome (MetS) is characterized by obesity, dyslipidemia, hyperglycemia, insulin resistance (IR) and hypertension. The mammalian target of rapamycin (mTOR) is a serine/threonine kinase with key roles in glucose and lipid metabolism, cell growth, survival and proliferation.
View Article and Find Full Text PDFCREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma.
Br J Haematol
November 2024
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Article Synopsis
- In follicular lymphoma (FL), doctors have trouble finding the best treatment because different patients have different types of the disease, except for one drug that helps some patients with a specific gene change.
- Researchers studied 21 patients with FL who were not getting better and were treated with two different drugs, everolimus and temsirolimus, to see how their gene changes affected treatment success.
- They found that patients who responded well to the drugs had more changes in a specific gene called CREBBP, suggesting that this gene can help predict which treatments might work better for FL patients.
Characterization of Effects of mTOR Inhibitors on Aging in Caenorhabditis elegans.
J Gerontol A Biol Sci Med Sci
November 2024
Institute of Healthy Ageing, and Research Department of Genetics, Evolution and Environment, University College London, London, UK.
Pharmacological inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway with rapamycin can extend lifespan in several organisms. Although this includes the nematode Caenorhabditis elegans, effects in this species are relatively weak and sometimes difficult to reproduce. Here we test effects of drug dosage and timing of delivery to establish the upper limits of its capacity to extend life, and investigate drug effects on age-related pathology and causes of mortality.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!